Toropko Mariia, Chuvpilo Sergey, Karabelsky Alexander
Gene Therapy Department, Sirius University of Science and Technology, Olympic Avenue, 1, 354340 Sochi, Russia.
Pharmaceutics. 2024 Jul 25;16(8):986. doi: 10.3390/pharmaceutics16080986.
MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression by inhibiting the translation of target transcripts. The expression profiles of miRNAs vary in different tissues and change with the development of diseases, including cancer. This feature has begun to be used for the modification of oncolytic viruses (OVs) in order to increase their selectivity and efficacy. OVs represent a relatively new class of anticancer drugs; they are designed to replicate in cancer tumors and destroy them. These can be natural viruses that can replicate within cancer tumor cells, or recombinant viruses created in laboratories. There are some concerns regarding OVs' toxicity, due to their ability to partially replicate in healthy tissues. In addition, lytic and immunological responses upon OV therapy are not always sufficient, so various OV editing methods are used. This review discusses the latest results of preclinical and clinical studies of OVs, modifications of which are associated with the miRNA-mediated mechanism of gene silencing.
微小RNA(miRNA)是一类短的非编码RNA,通过抑制靶转录本的翻译来调节基因表达。miRNA的表达谱在不同组织中有所不同,并随着包括癌症在内的疾病发展而变化。这一特性已开始用于溶瘤病毒(OV)的改造,以提高其选择性和疗效。OV是一类相对较新的抗癌药物;它们被设计用于在癌症肿瘤中复制并摧毁肿瘤。这些可以是能够在癌症肿瘤细胞内复制的天然病毒,也可以是在实验室中构建的重组病毒。由于OV能够在健康组织中部分复制,因此人们对其毒性存在一些担忧。此外,OV治疗后的裂解和免疫反应并不总是足够的,因此会使用各种OV编辑方法。本综述讨论了OV的临床前和临床研究的最新结果,其改造与miRNA介导的基因沉默机制有关。